Overall Survival (OS) Update: 2-year follow-up from the phase-3 RESORCE trial of Regorafenib for patients with hepatocellular carcinoma (HCC) progressing on Sorafenib
D. Waldschmidt, Alessandro Granito, Philippe Merle, Yi‐Hsiang Huang, G. Bodoky, Osamu Yokosuka, Olivier Rosmorduc, Валерий Владимирович Бредер, René Gerolami, Gianluca Masi, P.J. Ross, Susan Quinn, Tianqiang Song, JP Bronowicki, Isabelle Olivier-Hourmand, Masatoshi Kudo, MA LeBerre, Annette Baumhauer, Gudrun Meinhardt, Guorong Han, Jordi Bruix (2019). Overall Survival (OS) Update: 2-year follow-up from the phase-3 RESORCE trial of Regorafenib for patients with hepatocellular carcinoma (HCC) progressing on Sorafenib. , DOI: https://doi.org/10.1055/s-0039-1695314.
